December 3, 2023

Cac-Nm-Dnd-001 Cusabio

LysoBriteâ„¢ Red DND-99
22647-500Tests 500 Tests
EUR 166
Description: LysoBrite Red DND-99 is chemically same to the LysoTracker® Red DND-99 used for labeling and tracking acidic organelles in live cells (LysoTracker® is the trademark of ThermoFisher).

Cusabio Laboratories manufactures the cac-nm-dnd-001 cusabio reagents distributed by Genprice. The Cac-Nm-Dnd-001 Cusabio reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Cusabio. Other Cac-Nm-Dnd-001 products are available in stock. Specificity: Cac-Nm-Dnd-001 Category: Cusabio

ICG 001
100 mg
EUR 710
Description: CG001 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.

ICG 001
25 mg
EUR 330
Description: CG001 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.

ICG-001
  • EUR 1011.60
  • EUR 427.20
  • 25 mg
  • 5 mg

EPI-001
10 mg
EUR 157.2
Description: EPI-001 is a small-molecule inhibitor of androgen receptor N-terminal domain. EPI-001 could target the amino terminal domain of the AR and inhibit the protein-protein interactions which are necessary for AR transcriptional activity.

EPI-001
200 mg
EUR 714
Description: EPI-001 is a small-molecule inhibitor of androgen receptor N-terminal domain. EPI-001 could target the amino terminal domain of the AR and inhibit the protein-protein interactions which are necessary for AR transcriptional activity.

EPI-001
50 mg
EUR 351.6
Description: EPI-001 is a small-molecule inhibitor of androgen receptor N-terminal domain. EPI-001 could target the amino terminal domain of the AR and inhibit the protein-protein interactions which are necessary for AR transcriptional activity.

TOK-001
10 mg
EUR 282
Description: TOK-001 (Galeterone) is a novel small molecule that selectively target CYP17 and androgen receptor for prostate cancer treatment [1].

Test Assays information

ICG-001
20-abx076792
  • EUR 1011.60
  • EUR 427.20
  • 25 mg
  • 5 mg

EPI-001
B6041-10 10 mg
EUR 157.2
Description: EPI-001 is a small-molecule inhibitor of androgen receptor N-terminal domain. EPI-001 could target the amino terminal domain of the AR and inhibit the protein-protein interactions which are necessary for AR transcriptional activity.

EPI-001
B6041-200 200 mg
EUR 714
Description: EPI-001 is a small-molecule inhibitor of androgen receptor N-terminal domain. EPI-001 could target the amino terminal domain of the AR and inhibit the protein-protein interactions which are necessary for AR transcriptional activity.

EPI-001
B6041-50 50 mg
EUR 351.6
Description: EPI-001 is a small-molecule inhibitor of androgen receptor N-terminal domain. EPI-001 could target the amino terminal domain of the AR and inhibit the protein-protein interactions which are necessary for AR transcriptional activity.

TOK-001
A8623-10 10 mg
EUR 282
Description: TOK-001 (Galeterone) is a novel small molecule that selectively target CYP17 and androgen receptor for prostate cancer treatment [1].

TOK-001
A8623-5.1 10 mM (in 1mL DMSO)
EUR 199.2
Description: TOK-001 (Galeterone) is a novel small molecule that selectively target CYP17 and androgen receptor for prostate cancer treatment [1].

TOK-001
A8623-50 50 mg
EUR 714
Description: TOK-001 (Galeterone) is a novel small molecule that selectively target CYP17 and androgen receptor for prostate cancer treatment [1].

ICG 001
A8217-10 10 mg
EUR 211.2
Description: ICG001 is a small molecule inhibitor that targets Wnt/?-catenin pathway. It inhibits TCF/?-catenin mediated transcription by competing with ?-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM [1].

ICG 001
A8217-100 100 mg
EUR 868.8
Description: ICG001 is a small molecule inhibitor that targets Wnt/?-catenin pathway. It inhibits TCF/?-catenin mediated transcription by competing with ?-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM [1].

ICG 001
A8217-25 25 mg
EUR 412.8
Description: ICG001 is a small molecule inhibitor that targets Wnt/?-catenin pathway. It inhibits TCF/?-catenin mediated transcription by competing with ?-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM [1].

ICG 001
A8217-5 5 mg
EUR 151.2
Description: ICG001 is a small molecule inhibitor that targets Wnt/?-catenin pathway. It inhibits TCF/?-catenin mediated transcription by competing with ?-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM [1].

ICG 001
A8217-5.1 10 mM (in 1mL DMSO)
EUR 212.4
Description: ICG001 is a small molecule inhibitor that targets Wnt/?-catenin pathway. It inhibits TCF/?-catenin mediated transcription by competing with ?-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM [1].

ICG 001
A8217-S Evaluation Sample
EUR 97.2
Description: ICG001 is a small molecule inhibitor that targets Wnt/?-catenin pathway. It inhibits TCF/?-catenin mediated transcription by competing with ?-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM [1].

ICG-001
E1KS2662 5mg1​ PHYSICAL AND CHEMICAL PROPERTIES
EUR 625.2

RRx-001
HY-16438 100mg
EUR 2208

ICG-001
HY-14428 100mg
EUR 968.4

Rabbit anti-CAC Antibody
DL98095A-100ul 100 ul
EUR 325
Description: CAC; CACT; Mitochondrial carnitine/acylcarnitine carrier protein; Carnitine/acylcarnitine translocase; CAC; Solute carrier family 25 member 20